Regeneron Pharmaceuticals, Inc.
REGN today announced that it has received notification from the U.S.
Food and Drug Administration that the agency has extended its target
date to complete the priority review of the EYLEA Biologics License
Application for the treatment of neovascular age-related macular
degeneration to November 18, 2011, which is a three month extension
from the original Prescription Drug User Fee Act action date.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in